NCT04605588

A Triple Combination Antiviral Coronavirus Therapy (TriACT) for COVID-19

A Triple Combination Antiviral Coronavirus Therapy (TriACT) RCT Comparing Nitazoxanide, Ribavirin and Hydroxychloroquine vs. Placebo

• Status: Terminated
• Phase: Phase 2
• Study type: Interventional
• Enrollment: 7 (actual)
• Sponsor: Rutgers, The State University of New Jersey · Academic / Other
• Sex: All
• Age: 21 Years
• Healthy volunteers: Not accepted

Summary

New outpatient treatments for COVID-19 are urgently needed. There is some evidence that a combination of three medications currently used to treat other viral infections could be effective in fighting this new virus. The purpose of this trial is to evaluate the efficacy of Nitazoxanide (NTZ), Ribavirin (RBV) and Hydroxychloroquine (HCQ) versus placebo in participants with proven SARS-CoV-2 infection The study will enroll 70 participants within the 7 days after having been diagnosed with coronavirus infection. The purpose is to determine if those randomized to 5-day dosing with the three medication combination have decreased viral load and severity of illness in the 10 days following treatment as compared to those taking placebo. Participants will be actively followed for 28 days.

Detailed description

Participants will be randomized into one of two treatment plans * Triple combination: * Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days) * Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days) * Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days) * No active Medication: * Placebo administered according to the above schedule Viral load (qPCR via nasal swab) will be assessed at baseline (day 0) as well as at days 3, 6, and 10 to monitor response to antiviral treatment. Immune status will be determined by antibody testing of blood collected at baseline and day 28. Symptom questionnaires will be completed daily for 10 days and day 28.

Conditions

• SARS-CoV Infection
• Covid19

Interventions

Type	Name	Description
DRUG	Nitazoxanide	Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
DRUG	Placebo Nitazoxanide	Placebo Nitazoxanide (500 mg po BID for day 1and then 500 mg BID for 4 days)
DRUG	Ribavirin	Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
DRUG	Placebo Ribavirin	Placebo Ribavirin (600 mg po BID for day 1and then 400 mg BID for 4 days)
DRUG	Hydroxychloroquine	Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)
DRUG	Placebo Hydroxychloroquine	Placebo Hydroxychloroquine sulfate (400 mg po BID for day 1 and then 200 mg BID for 4 days)

Timeline

• Start date: 2020-12-02
• Primary completion: 2021-01-17
• Completion: 2021-02-04
• First posted: 2020-10-28
• Last updated: 2022-05-05
• Results posted: 2022-05-05

Locations

1 site across 1 country: United States

Regulatory

• FDA-regulated drug study